Bioimpedance in monitoring of effects of selective serotonin reuptake inhibitor treatment

Vasiliy Grigorievich Alexeev, Ludmila Vasilievna Kuznecova, Vasiliy Grigorievich Alexeev, Ludmila Vasilievna Kuznecova

Abstract

Background: Bioimpedance has been shown to be a safe technique when used in a number of biomedical applications. In this study, we used the Electro Interstitial Scan (EIS) to perform bioimpedance measurements to follow up the efficacy of selective serotonin reuptake inhibitor (SSRI) treatment in subjects diagnosed to have major depressive disorder.

Methods: We recruited 59 subjects (38 women, 21 men) aged 17-76 (mean 47) years diagnosed with major depressive disorder by psychiatric assessment at the Botkin Hospital according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Baseline Clinical Global Impression scores and EIS (electrical conductivity and dispersion α parameter) measurements were done before starting SSRI therapy. Treatment follow-up was undertaken using EIS bioimpedance measurements and by treatment response based on the Hamilton Depression Scale and Clinical Global Impression, every 15 days for 60 days. At day 45, we classified the patients into two groups, ie, Group 1, including treatment responders, and Group 2, including nonresponders. At day 60, patients were classified into two further groups, ie, Group 3, comprising treatment responders, and Group 4, comprising nonresponders.

Results: Comparing Group 1 and Group 2, electrical conductivity measurement of the pathway between the two forehead electrodes had a specificity of 72% and a sensitivity of 85.3% (P < 0.0001), with a cutoff >4.32. Comparing Group 3 and Group 4, electrical conductivity measurements in the same pathway had a specificity of 47.6% and a sensitivity of 76.3% (P < 0.16), with a cutoff >5.92. Comparing Group 1 and Group 2, the electrical dispersion α parameter of the pathway between the two disposable forehead electrodes had a specificity of 80% and a sensitivity of 85.2% (P < 0.0001) with a cutoff >0.678. Comparing Group 3 and Group 4, the electrical dispersion α parameter of the same pathway had a specificity of 100%, a sensitivity of 89.5% (P < 0.0001), and a cutoff >0.692.

Conclusion: Electrical conductivity measurement of the forehead pathway using EIS has a high specificity and sensitivity at day 45 when comparing treatment responders and nonresponders, but decreases at day 60. The EIS electrical dispersion α parameter of the forehead pathway has a high specificity and sensitivity at day 45 when comparing treatment responders and nonresponders, and increases at day 60. The EIS system may be a noninvasive, easily administered, low-cost technique that could be used as an adjunct to DSM-IV and Clinical Global Impression scores for monitoring of efficacy of treatment in patients with major depressive disorder.

Keywords: Electro Interstitial Scan; dispersion α parameter; electrical conductivity; major depressive disorder; selective serotonin reuptake inhibitors.

Figures

Figure 1
Figure 1
Comparing Group 1 (D+45 responders) and Group 2 (D+45 nonresponders), electrical conductivity measurement of the pathway between the two forehead electrodes. Note: aBinomial exact.
Figure 2
Figure 2
Comparing Group 3 (D+60 responders) and Group 4 (D+60 non responders), electrical conductivity measurement of the pathway between the two forehead electrodes. Note: aBinomial exact.
Figure 3
Figure 3
Comparing Group 1 (D+45 responders) and Group 2 (D+45 nonresponders), electrical dispersion of the pathway between the two forehead electrodes Note: aBinomial exact.
Figure 4
Figure 4
Comparing Group 3 (D+60 responders) and Group 4 (D+60 nonresponders), electrical dispersion of the pathway between the two forehead electrodes. Note: aBinomial exact.

References

    1. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA. 1989;262:914–919.
    1. Montano CB. Recognition and treatment of depression in a primary care setting. J Clin Psychiatry. 1994;55( Suppl 12):18–34.
    1. Wells BG. Issues in the diagnosis of major depression. Formulary. 1995;30( Suppl 1):S3–S9.
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington, DC: American Psychiatry Association; 1994.
    1. US Department of Health, Education, and Welfare. Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 1976.
    1. Trivedi MH, Kurian BT, Grannemann BD. Clinical predictors in major depressive disorder. Psychiatry Weekly. [Accessed on May 21, 2007]. Available from: .
    1. Hamilton M. Rating depressive patients. J Clin Psychiatry. 1980;41:21–24.
    1. Rigaud B, Morucci J, Chauveau N. Bioelectrical impedance techniques in medicine. Part I: bioimpedance measurement. Second section: impedance spectrometry. Crit Rev Biomed Eng. 1996;24:257–351.
    1. Woltjer HH, Bogaard HJ, de Vries JM. The technique of impedance cardiography. Eur Heart J. 1997;18:1396–1403.
    1. Ko HW, Smith DG, Skura JP. In vitro measurements of brain edema with the magnetic bio-impedance method. Presented at the annual conference of the IEEE Engineering in Medicine and Biology Society; Amsterdam, The Netherlands. October 31–November 3; 1996.
    1. De Abreu DS. Bioimpedance and chronoamperometry as an adjunct to prostate-specific antigen screening for prostate cancer. Cancer Manag Res. 2011;3:109–116.
    1. Grimmes S, Martinsen ØG. Electrolytics in Bioimpedance and Bioelectricity Basics. San Diego, CA: Academic Press; 2000.
    1. Cottrell FG. Application to the Cottrell equation to chronoamperometry. Z Physik Chem. 1902;42:385.
    1. Cole KS, Cole RH. Dispersion and absorption in dielectrics. I. Alternating-current characteristics. J Chem Phys. 1941;9:341–351.
    1. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–845.
    1. Ivorra A, Genescà M, Sola A, et al. Bioimpedance dispersion width as a parameter to monitor living tissues. Physiol Meas. 2005;26:1–9.
    1. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ. 1993;306:683–687.
    1. Fabre LF, Putman HP. A fixed-dose clinical trial of fluoxetine in outpatients with major depression. J Clin Psychiatry. 1987;48:406–408.
    1. Bruder GE, Stewart JW, Tenke CE, et al. Electroencephalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant. Biol Psychiatry. 2001;49:416–425.

Source: PubMed

3
Subskrybuj